The Paris Private Equity team advises SparingVision as it has entered into a definitive agreement for the acquisition of GAMUT Therapeutics, a biotechnology company developing a unique gene-independent approach to treat advanced stages of rod and cone dystrophies.
This acquisition reflects SparingVision's commitment to becoming a leader in the field of genomic medicine for ocular diseases by identifying and developing innovative solutions from the synergy of the two companies.
As part of the acquisition agreement, SparingVision will be able to participate in the creation of a new cell therapy company, which would be launched by the founding shareholders of GAMUT.
SparingVision is a French biotechnology company focused on the discovery and development of genomic medicines for the treatment of blinding inherited retinal diseases.
The Goodwin team was led, in Paris, by William Robert and Marie-Laure Bruneel on tax aspects, and in Cambridge, Malcom Bates on due diligence and negotiation aspects related to licensing and collaboration agreement.